Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 134-148, May 2010

Major and minor salivary gland tumors

  • Marco Guzzo

      Affiliations

    • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
  • ,
  • Laura D. Locati

      Affiliations

    • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
  • ,
  • Franz J. Prott

      Affiliations

    • Radiotherapy, Wiesbaden, Germany
  • ,
  • Gemma Gatta

      Affiliations

    • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
  • ,
  • Mark McGurk

      Affiliations

    • Guy's and St. Thomas’ Hospital Trust, London, UK
  • ,
  • Lisa Licitra

      Affiliations

    • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
    • Corresponding Author InformationCorresponding author at: Head and Neck Medical Oncology Unit, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Via Venezian 1, 20133 Milano, Italy. Tel.: +39 02 23903352; fax: +39 02 23903353.

Accepted 20 October 2009. published online 26 November 2009.

Abstract 

Malignant salivary gland tumors are rare. The most common tumor site is the parotid. Aetiologic factors are not clear. Nutrition may be a risk factor, as well as irradiation or a long-standing histologically benign tumor that occurs at youth. Painless swelling of a salivary gland should always be considered as suspicious, especially if no sign of inflammation is present. Signs and symptoms related to major salivary gland tumors differ from those concerning minor salivary gland tumors, as they depend on the different location of the salivary gland. Surgical excision represents the standard option in the treatment of resectable tumors of both major and minor salivary glands. Neutron, heavy ions or proton radiotherapy may be a treatment option for inoperable locoregional disease. Surgery, irradiation or re-irradiation are treatment options for local relapse, whereas radical neck dissection is indicated for regional relapses. Metastatic disease may be either treated with radiotherapy or palliative chemotherapy, depending on the site of metastases. For highly selected patients the employment of anti-androgen therapy is indicated.

Keywords: Evidence-based medicine, Review, Salivary gland tumors, Treatment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1040-8428(09)00217-0

doi:10.1016/j.critrevonc.2009.10.004

Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 134-148, May 2010